DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dianthus Therapeutics (DNTH) had its price target raised by Guggenheim from $100.00 to $200.00. They now have a "buy" rating on the stock.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Point72 Asset Management, L.P.
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form 4 Dianthus Therapeutics, For: Feb 03 Filed by: CARR EDWARD
Form 4 Dianthus Therapeutics, For: Feb 03 Filed by: Veness Adam M
Form 4 Dianthus Therapeutics, For: Feb 03 Filed by: Randhawa Simrat
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.